SCHEMBL4597791

SCHEMBL4597791

NC(Cc1ccc(Oc2cccc(C(=O)NO)c2)cc1)C(=O)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.49
RAB9A P51151 1/20 0.47
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 1/20 0.46
MMP8 P22894 1/20 0.44
MEN1 O00255 2/20 0.44
NTRK1 P04629 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 1/20 0.42
SMPD1 P17405 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KDM1A O60341 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5121832 0.91 MMP8 (0.47) HDAC8MMP8ALDH1A1KDM1AHDAC1
SCHEMBL4596780 0.90 HDAC8 (0.51) HDAC8SMPD1HDAC1
SCHEMBL4598222 0.88 HDAC8 (0.49) HDAC8SMPD1HDAC1
SCHEMBL4597882 0.81 HDAC8 (0.64) HDAC8LMNASMN1; SMN2ALDH1A1SMPD1
SCHEMBL5129878 0.80 TSHR (0.45) HDAC8LMNASMN1; SMN2KMT2AMMP8
SCHEMBL5124921 0.80 HDAC1 (0.48) HDAC8HDAC1
SCHEMBL14115840 0.80 FKBP1A (0.46) RAB9ASMN1; SMN2NPC1MMP8ALDH1A1
SCHEMBL14021683 0.80 FKBP1A (0.46) RAB9ASMN1; SMN2NPC1MMP8ALDH1A1
Hydrochloric Acid SCHEMBL4596783 0.79 FKBP1A (0.46) HDAC8RAB9ASMN1; SMN2NPC1MMP8
SCHEMBL4598564 0.77 HDAC8 (0.55) HDAC8LMNASMN1; SMN2ALDH1A1SMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives BEXEL PHARMACEUTICALS. INC. 2008-08-21 US claimed
EP-1906731-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES Bexel Pharmaceuticals Inc (US) 2008-04-09 EP claimed
WO-2007005603-A2 NOVEL HYDROXAMIC ACID-CONTAINING AMINO ACID DERIVATIVES BEXEL PHARMACEUTICALS, INC. (US) 2007-01-11 WO claimed
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives BEXEL PHARMACEUTICALS, INC. 2007-01-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200521-A1 Novel hydroxamic acid containing amino acid derivatives HGFAC, HCAR2, BCAT1 HDAC8 154/4885RAB9A 4557/4885LMNA 3014/4885
US-20070004776-A1 Novel hydroxamic acid-containing amino acid derivatives HGFAC, HCAR2, BCAT1 HDAC8 176/4885RAB9A 4582/4885LMNA 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.